Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 6/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070011 | 0.78 | HTR2A (0.47) | EGFRKCNH2MCHR1CNR1CNR2 | |
| SCHEMBL29533972 | 0.75 | CHEK1 (0.47) | EGFRKCNH2MCHR1HTR2AHTR2C | |
| SCHEMBL6070377 | 0.75 | CHEK1 (0.47) | EGFRKCNH2MCHR1HTR2AHTR2C | |
| SCHEMBL5427359 | 0.73 | CNR1 (0.34) | EGFRCNR1CNR2ADORA2AADORA1 | |
| SCHEMBL31351306 | 0.73 | HTR1D (0.44) | EGFRKCNH2MCHR1 | |
| SCHEMBL31351105 | 0.73 | CARM1 (0.40) | EGFRKCNH2MCHR1HTR2AHTR2C | |
| SCHEMBL17678355 | 0.71 | KMO (0.61) | EGFRKCNH2MCHR1HTR2AHTR2C | |
| SCHEMBL25975946 | 0.71 | KMO (0.47) | EGFRKCNH2MCHR1HTR2AHTR2C | |
| SCHEMBL6069750 | 0.70 | HTR2A (0.44) | EGFRKCNH2MCHR1HTR2AHTR2C | |
| SCHEMBL23533615 | 0.70 | EGFR (0.55) | EGFRKCNH2MCHR1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297833-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma AG (DE) | 2016-10-13 | — | — | US | disclosed |
| EP-3071577-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015074986-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297833-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, DTYMK | EGFR 2190/4885KCNH2 3230/4885MCHR1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.